Project Grant K08AI187792
Award Date 8/19/26
Completion Date 7/31/31
Dollars Obligated $206K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $806,000 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of secreted bacterial effectors in Group B Streptococcus (GBS) intestinal colonization and systemic neonatal infection. The research examines how GBS type VII secretion system effectors promote intestinal dysbiosis, impair immune responses, disrupt intestinal barrier function, and...
- The National Institute of Allergy and Infectious Diseases awarded The Research Foundation For The State University Of New York (operating as SUNY at Binghamton) $313,382 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of a two-component regulatory system in Group B Streptococcus (GBS), focusing on environmental sensing and signal transduction through the SAERS system and characterization of the BVAP protein and its...
- Federal Grant Award Summary Seattle Children's Research Institute received a $3.61 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 14, 2025, with a completion date of June 30, 2029. This research project investigates hyaluronidase (HylB), a virulence factor produced by Group B Streptococci (GBS), to elucidate mechanisms by which the enzyme suppresses immune...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Methodist Hospital Research Institute a Project Grant of $444,125 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2027. This research project will characterize a previously unknown intercellular signaling pathway in Group B Streptococcus (GBS) and determine its contribution to bacterial pathogenesis. Specifically,...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $250,888 to the University of Colorado-Denver on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of Group B Streptococcal type VII secretion systems in diabetic wound infections. The project will characterize how Streptococcus agalactiae persists and interacts with co-infecting bacteria in polymicrobial...
- The National Institute of Allergy and Infectious Diseases awarded $231,000 to the Regents of the University of Minnesota on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the paradoxical role of antibiotic therapy in increasing the risk of Guillain-Barré syndrome (GBS), an acute autoimmune neuropathy. The work examines how antibiotics upregulate lipooligosaccharide (LOS) production in Campylobacter jejuni, the leading...
- The National Institute of Allergy and Infectious Diseases awarded New York University a Project Grant of $791,797 on February 4, 2026, to investigate intestinal programming of gut-associated germinal centers under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research examines how the intestinal microbiota directs differential programming of local B cell responses toward production of regulatory immunoglobulin A (IgA) in gut-associated germinal centers. IgA, produced by...
- The National Institute of Allergy and Infectious Diseases awarded $157,356 to the University of Georgia Research Foundation, Inc. on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct strain-resolved metagenomics analysis of Bifidobacterium infantis colonization in early infancy and its associations with child health outcomes. The research generates shotgun metagenome data from biobanked infant stool samples collected through the ECOMID birth...
- Federal Grant Award Summary The New York Structural Biology Center, Inc. (NYSBC) received a $518,400 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award funds research to determine the three-dimensional architecture of an internal ribosome entry site (IRES) from Giardia lamblia virus (GLV), a pathogenic organism causing giardiasis, the most...
- The National Institute of Allergy and Infectious Diseases awarded Beth Israel Deaconess Medical Center, Inc. $987,730 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop next-generation spectinomycin analogs that evade adenylase-based resistance mechanisms and demonstrate enhanced potency against multidrug-resistant gram-negative pathogens including carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. The...